Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

Clinical trial NCT05757336 · RECRUITING

Trial details

NCT number: NCT05757336
Sponsor: Lu Wang, MD, PhD
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Gallbladder Cancer Initially Unresectable the First Line Treatment

Start date: 2022-12-22
Primary completion: 2024-12-22
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.